Upload
duongkien
View
222
Download
3
Embed Size (px)
Citation preview
BREAKING THE BENZO CYCLE- ALTERNATIVES TO TREATING ANXIETY DISORDERS
Rebecca Dorsey, RN, MSN, PMHNP-BC, FNP-BC
Portland, Oregon
OBJECTIVES
1
1. Discuss the challenges of treating anxiety
2
2. Identify the pathophysiology of anxiety to include a brief review of brain structure and applicable neurotransmitters
3
3. Summarize new research evidence on the long-term use of benzodiazepines
4
4. Explore the limited role of benzodiazepines and treatment alternatives for common anxiety disorders
BENZODIAZEPINE USE HAS REACHED EPIDEMIC LEVELS…
- Between 1996 and 2013, the number of adults filing a prescription for a benzodiazepine increased 67% from 8.1million to 13.5 million (Bachuber, Hennessy, Cunningham, Starrels, 2016)
CONSEQUENCE OF LONG-TERM USE
- Loss of efficacy over time
- Emotional blunting
- Cognitive dulling
- Memory loss and impaired learning
ALZHEIMER’S DISEASE AND DEMENTIA
Benzodiazepine use, for periods of over 3 months, show an overall increase in dementia diagnosis of 51%. (James, 2017)
The strength of association increases 30% when comparing the long-term use of short-acting to long-acting benzodiazepines. (Gage, Maride, Ducruet, Kruth, Vedoux, Tournier, Periente, and Begaud, 2014)
WITHDRAWAL SYMPTOMS
- agitation, anxiety, and dysphoria
- increased awareness of sensory stimuli
- perceptual disturbances and depersonalization
- confusion, delirium, and seizures
- with abrupt discontinuation an appreciable increase in arterial pressure could result in myocardial ischemia
MOST COMMONLY SEEN ANXIETY DISORDERS IN CLINIC:
- GENERALIZED ANXIETY DISORDER
- SOCIAL ANXIETY DISORDER
- PANIC DISORDER
- POST-TRAUMATIC STRESS DISORDER
REGARDLESS OF THE FORMAL DIAGNOSIS, ANXIETY CAN BE BROKEN DOWN INTO TWO PRIMARY CATEGORIES OF SYMPTOMS:
FEAR AND WORRY
Stahl, 2013
SSRI SNRI A2L* BZ* BUSP* REM* ATYP* MAOI BB* TRZ* AH*GAD 1st 1st 1st 2nd 1st 2nd Adj 2nd 2nd
PANIC 1st 1st 2nd 2nd Adj 2nd
SAD 1st 1st 1st 2nd 2nd 2nd
PTSD 1st 1st 2nd 2nd 2nd
Key:A2L- Alpha 2 Ligands ATYP- Atypical AntipsychoticBZ- Benzodiazepine BB- Beta BlockerBUSP- Buspirone TRZ- TrazodoneREM- Remeron AH- Antihistamines
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
1. Sertraline/ Zoloft
2. Fluoxetine / Prozac
3. Paroxetine / Paxil
4. Fluvoxamine / Luvox
5. Citalopram / Celexa
6. Escitalopram / Lexapro
ALPHA2 LIGANDS
Gabapentin and Pregabalin (bind to voltage sensitive calcium channels which blocks excitatory neurotransmitters that results in fear and worry)
BUSPIRONE / BUSPAR
Binds to serotonin type 1A receptors to help address symptoms of both anxiety and depression
Partial agonist actions post-synaptically may diminish serotonergic activity (anxiety)
Partial agonist actions pre-synaptically at serotonin autoreceptors may enhance serotonergic activity (depression)
MIRTAZAPINE / REMERON
Alpha 2 antagonist
NaSSA (noradrenaline and specific serotonergic agent)
Dual Serotonin and NE agent
Blocks H1 histamine receptors
ATYPICAL ANTIPSYCHOTICS
1. Quetiapine / Seroquel
2. Aripiprazole / Abilify
3. Olanzapine / Zyprexa
4. Risperidone / Risperdal
MONOAMINE OXIDASE INHIBITORS
1. Isocarboxazid / Marplan
2. Phenelzine / Nardil
3. Selegiline / Emsam
4. Tranylcypromine / Parnate
PEARLS
Establish guidelines and boundaries with patients from the beginning - Consider a formal benzo agreement
If you start it, be prepared to manage it
Use an established formula for discontinuation http://www.benzo.org.uk/manual (Ashton Manual)
Once you set a taper plan, follow-through
REFERENCES
• Bachhumber, Hennessy, Cunningham, and Starrels (2016). Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. AJPH. 106(4) 686-688.
• Gage, Moride, Ducruet, Kurth, Verdoux, Tournier, Pariente, and Begaud (2014). Benzodiazepine use and Risk of Alzheimer’s Disease: case-control study. https://www.ncbi.nlm.nih.gov/pubmed/26123874
• James (2017). Hypnotics and Risk of Dementia. Clinical Journal of Sleep Medicine. 3(6) 837-839.• National Health Service (2008). Guidance for Prescribing &Withdrawal of Benzodiazepines &
Hypnotics in General Practice. www.benzo.org.uk/amisc/bzgrampian.pdf• NIMH (2014) Press release: Despite risks, benzodiazepine use highest in older people.
https://www.nimh.nih.gov/news/science-news/2014/despite-risks-benzodiazepine-use-highest-in-older-people.shtml
• Pliska (2003). Neuroscience for the Mental Health Clinician. New York: The Guilford Press.• Stahl (2014). Stahl’s Essential Psychopharmacology: Prescriber’s Guide. San Diego, California:
Cambridge University Press.• Stahl (2013). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical
Application. New York: Cambridge University Press.